Properties and modeling of GWAS when complex disease risk is due to non-complementing, deleterious mutations in genes of large effect. by Thornton, Kevin R et al.
UC Irvine
UC Irvine Previously Published Works
Title
Properties and modeling of GWAS when complex disease risk is due to non-complementing, 
deleterious mutations in genes of large effect.
Permalink
https://escholarship.org/uc/item/3mv086mz
Journal
PLoS genetics, 9(2)
ISSN
1553-7390
Authors
Thornton, Kevin R
Foran, Andrew J
Long, Anthony D
Publication Date
2013
DOI
10.1371/journal.pgen.1003258
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Properties and Modeling of GWAS when Complex
Disease Risk Is Due to Non-Complementing, Deleterious
Mutations in Genes of Large Effect
Kevin R. Thornton*, Andrew J. Foran, Anthony D. Long*
Department of Ecology and Evolutionary Biology, University of California Irvine, Irvine, California, United States of America
Abstract
Current genome-wide association studies (GWAS) have high power to detect intermediate frequency SNPs making modest
contributions to complex disease, but they are underpowered to detect rare alleles of large effect (RALE). This has led to
speculation that the bulk of variation for most complex diseases is due to RALE. One concern with existing models of RALE is
that they do not make explicit assumptions about the evolution of a phenotype and its molecular basis. Rather, much of the
existing literature relies on arbitrary mapping of phenotypes onto genotypes obtained either from standard population-
genetic simulation tools or from non-genetic models. We introduce a novel simulation of a 100-kilobase gene region, based
on the standard definition of a gene, in which mutations are unconditionally deleterious, are continuously arising, have
partially recessive and non-complementing effects on phenotype (analogous to what is widely observed for most
Mendelian disorders), and are interspersed with neutral markers that can be genotyped. Genes evolving according to this
model exhibit a characteristic GWAS signature consisting of an excess of marginally significant markers. Existing tests for an
excess burden of rare alleles in cases have low power while a simple new statistic has high power to identify disease genes
evolving under our model. The structure of linkage disequilibrium between causative mutations and significantly associated
markers under our model differs fundamentally from that seen when rare causative markers are assumed to be neutral.
Rather than tagging single haplotypes bearing a large number of rare causative alleles, we find that significant SNPs in a
GWAS tend to tag single causative mutations of small effect relative to other mutations in the same gene. Our results
emphasize the importance of evaluating the power to detect associations under models that are genetically and
evolutionarily motivated.
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Introduction
Genome-wide association studies (GWAS) genotype upwards of
500,000 common SNPs and test for allele frequency differences in
case/control panels consisting of several thousand individuals.
Such studies have identified highly significant and replicable
associations, and as a result have uncovered entirely new pathways
contributing to complex disease risk (http://www.genome.gov/
gwastudies/). However, these associations explain only a small
fraction of the known heritability of risk for the diseases examined
[1]. It is well-known that the GWAS paradigm of testing for
associations primarily using intermediate frequency markers has
high power to identify an association only if disease causing alleles
are also at intermediate frequency [2]. This ‘‘missing heritability’’
has led to speculation that a new round of GWAS should be
designed to detect rarer variants of presumably larger effect. The
potential importance of rare alleles of large effect (RALE) is
supported empirically by studies that have carried out deep
resequencing of candidate gene exons and observed an excess of
rare radical amino acid polymorphisms in cases relative to controls
for a variety of diseases (HDL cholesterol levels [3], susceptibility
to colorectal adenomas [4], LDL cholesterol levels [5], triglyceride
levels [6], folate metabolism [7], and hypertriglyceridemia
susceptibility [8]. Collectively, these studies suggest the possibility
that the same sort of genetic heterogeneity commonly observed for
Mendelian disorders [9,10]) may characterize complex disease.
A weakness of the RALE model for complex disease variation is
that it is not a population-genetic model, but rather an easy to
understand verbal model. As a result it does not make quantitative
predictions concerning the nature of genetic variation at the genes
underlying complex disease, neither in terms of the number of
causative alleles, their frequencies and effects, nor in terms of the
patterns of linkage disequilibrium (LD) between causative alleles
and linked neutral markers. Ideally, the predictions of various
RALE models would come from explicit population-genetic
models of disease, with concrete assumptions about the fitness
effects of causative mutations and the relationship between
phenotype and fitness determining the frequency of causative
mutations in the population. To date, Prichard’s [11] work is the
best attempt to model the impact of the equilibrium between
mutation and selection on the frequencies of disease-risk muta-
tions. His model generates scenarios where the genetic basis of a
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complex disease consists of many rare mutations at different sites
within a gene, with the frequency of causative mutations being
determined by the balance of mutation and natural selection [12].
His model is a case for which the power of standard association
tests is greatly reduced [2,13,14].
Pritchard’s [11] work did not model intragenic recombination,
nor track neutral mutations partially-linked to causative deleteri-
ous mutations. Thus, Pritchard was unable to explicitly address the
power of GWA studies, which genotype both causative and linked
neutral SNP markers throughout the genome. This question
instead requires the use of explicit simulations of an evolving
phenotype and its molecular basis. In recent work, the application
of population-genetic principles to understanding the properties of
GWAS have been highly heterogeneous. For example, some
authors have modeled the frequencies of risk alleles in a region as
independent random variables, as opposed to simulating a
recombining region [15–17]. In these studies, the genotype/
phenotype relationship is based on arbitrary choices as to the
number of causative mutations [15–17]. A second set of studies
have simulated recombining regions using coalescent simulations
without selection [e.g., 18] to generate a large set of haplotypes
from a model with explicit assumptions about demography (these
assumptions vary from study to study) [19–21]. The authors then
selected an arbitrary number of mutations from arbitrary
frequency ranges to be causative mutations, and arbitrary effect
sizes are assigned. Finally, some studies have used forward
simulation machinery [e.g., 22] to simulate multiple partially-
linked deleterious mutations subject to natural selection in a region
interspersed with neutral mutations [23–25]. In these forward
simulations, fitness values were assigned to particular sites
according to genotype, and the final fitness of a diploid is typically
either the sum or product of fitness effects over deleterious
mutations. The simulation output is then used to map genotype to
phenotype using either an arbitrary model [24,25] or an explicit
quantitative genetic model [23]. Although this last class of models
represents the most sophisticated application of evolutionary
simulations, they are still limited in that the phenotype itself is
not the target of natural selection (as is the case in [11]), and thus
the simulated distributions of phenotypes are not the outcome of
an evolutionary process (even though the underlying mutation
frequencies are).
Here, we propose an explicit model of a quantitative trait
subject to natural selection, with case/control status treated as a
liability trait. Our model is similar to that of Pritchard [11] in that
the frequencies of deleterious mutations are the result of the
balance between mutation and natural selection [12], and similar
to other recent work [23,24,25] in employing explicit forward
simulations. We depart from existing work using forward
simulations in two important ways. First, the phenotype itself
determines fitness and thus is the target of natural selection.
Second, our model of gene action is based on the standard
definition of a gene as a region in which recessive mutations fail to
complement [26], such that affected individuals will generally be a
trans-heterozygote for causative mutations (e.g. heterozygous for at
least two different causative mutations at different positions in the
gene region), as is commonly-observed for Mendelian disorders
[10,27]. Our model of fitness is, therefore, based on the partial
recessivity of haplotypes and not on the standard population-
genetic assumptions of multiplicative or additive fitness across
individual mutations. Under these standard assumptions (used in
simulation programs such as [22]), fully-recessive mutations at
different positions complement one another in terms of fitness
(e.g., the fitness of a trans-heterozygote is the same as a diploid that
is homozygous for wild-type alleles at both sites) and, therefore, the
different deleterious mutations within a simulated region are,
themselves, different genes (sensu [26]). We develop a novel
forward simulation and use it to simulate a ‘‘typical’’ 100 kilobase
region of the human genome, tracking both causative deleterious
and non-causative neutral mutations. In our simulations, disease
risk is due to an underlying continuously varying liability score,
with a causative disease ‘‘gene’’ contributing ,5% to variation in
that score. Given the size of the region considered, the idea that
the vast majority of mutations are neutral, and the nature of gene
action being modeled, our models are most consistent with
mutations impacting both the structural product and the cis-
regulatory regions controlling expression of a gene contributing to
risk of a complex disease. We use our simulation machinery to
explore the population-genetic signals of selection against causa-
tive sites, and to explore the power of GWAS to test the hypothesis
that variation within a gene region contributes to complex disease.
Our model results in gene regions evolving under the ‘‘allelic
heterogeneity’’ model involving many non-complementing risk
mutations segregating within a gene region. Since the 1990s, many
human geneticists believed that this model was likely to explain
complex variation [9, pg 492; 10]. Under this model, complex
traits are genetically analogous to Mendelian disease genes, but the
mutations are simply less penetrant due to other genes and
environmental variation impacting the trait [9, Chapt. 14&15].
Our model results in weak selection against causal variants, with
no detectable average effect on patterns of variation at linked
neutral sites. A major finding is that statistical tests designed to
detect an overall greater number of rare alleles in cases have very
low power (such tests have been argued to have high power to
detect RALE), and less power than the standard single-marker
logistic regression assuming an additive model. The frequencies of
significant associations from single-marker tests applied to our
simulated GWAS involving common markers are consistent with
empirical observations from real GWA studies [28], in contrast to
previous results based on simulating RALE as neutral [19,28]. We
propose a simple statistic based on the excess of marginally
significant markers in a region, and find that it has higher power to
detect associations than other tests considered, although the power
Author Summary
Current GWA studies typically only explain a small fraction
of heritable variation in complex traits, resulting in
speculation that a large fraction of variation in such traits
may be due to rare alleles of large effect (RALE). The most
parsimonious evolutionary mechanism that results in an
inverse relationship between the frequency and effect size
of causative alleles is an equilibrium between newly arising
deleterious mutations and selection eliminating those
mutations, resulting in an inverse relation between effect
size and average frequency. This assumption is not built
into many current models of RALE and, as a result, power
calculations may be misleading. We use forward popula-
tion genetic simulations to explore the ability of GWAS to
detect genes in which unconditionally deleterious, partially
recessive mutations arise each generation. Our model is
based on the standard definition of a gene as a region
within which loss-of-function mutations fail to comple-
ment, consistent with the multi-allelic basis for Mendelian
disorders. Our model predicts that it may not be
uncommon for single genes evolving under our model
to contribute upwards of 5% to variation in a complex
trait, and that such genes could be routinely detected via
modified GWAS approaches.
GWAS and Disease Risk Due to Mutations in Genes
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of the SKAT package [21,29,30] can have comparable power.
Finally, in our simulations, the explanation for missing heritability
in current GWAS in that significantly associated common markers
tend to be associated with causative mutations with relatively small
effect sizes, but fail to tag rarer variants of larger effect. The
observation that more subtle-effect variants can drift to higher
allele frequencies is consistent with population-genetic predictions
of an inverse relationship between average frequency and effect on
fitness [e.g., 23], which we expect to be a general property of any
model involving mutation-selection balance. This explanation for
missing heritability differs from the hypothesis of ‘‘synthetic
associations’’ arising when RALE are assumed to be neutral
[19]. The simulated datasets represent an important resource for
evaluating the power of novel test statistics under the heterogeneity
model.
Results
An intuitive gene-based model results in weak selection
against affected individuals
Under our gene-based model, the effect size of a causative
mutation is exponentially-distributed with mean l (l=0 implies a
mutation that does not contribute to a complex disease pheno-
type), and the effect of a maternal or paternal haplotype is additive
over causative mutations. The phenotype of a diploid is the
geometric mean effect of the maternal and paternal haplotype plus
a random Gaussian environmental effect scaled so that the gene-
region being modeled accounts for some fraction of the total
disease burden. Figure 1a shows the difference between our model
of gene action (non-complementation of loss-of-function muta-
tions) and the standard population-genetic assumption that
mutation effects are multiplicative. By setting the contribution of
a gene to an individual’s phenotype equal to the geometric mean
of the maternal and paternal haplotypes, the haplotype closer to
being mutation-free dominates the genotypic effect (Figure 1b),
resulting in partially recessive model of gene-action (Figure S1a),
which is empirically supported for mutations of moderate effect
[31–34]. As in Pritchard’s work [11], the distribution of effect sizes
at causative sites at equilibrium is not equivalent to the distribution
of newly arising mutations. Rather, the frequency distribution of
causative mutations at equilibrium is determined by a balance of
mutation, genetic drift, and natural selection. This contrasts with
other attempts to model the frequency distribution of causative
mutations using an arbitrarily defined statistical distribution (as in
[17]) or arbitrary numbers of causative mutations [19,21,29]. Our
approach also differs from previous approaches in that the number
of causative mutations in a region is a random variable, as opposed
to a fixed an arbitrary quantity [15,16,19,21,29,35]. Insomuch as
the assumptions of our model are correct, we are properly
specifying the equilibrium distribution of the number, frequencies,
and effects of causative mutations, as well as the extent of LD
between causative and linked neutral sites.
In our simulated populations, liabilities are close to normally
distributed, except in the extreme ‘‘diseased’’ tail, where there is a
slight excess of extremely affected individuals (Figure 1c). Further,
the fitness of an affected individual is generally high (Figure S1b),
meaning that even individuals with the most extreme liabilities are
capable of approximately normal reproduction. Although there is
considerable uncertainty surrounding the distribution of fitness in
human populations, and the strength of purifying selection on
complex diseases remains a subject of debate, our model is
consistent with the idea that purifying selection on complex disease
phenotypes is generally weak, as has been claimed in the literature
[36].
The heritability due to single genes under our model
Given the computational demands of forward simulation, we
focus our attention on a set of parameters (see Methods) that
results in the proportion of total phenotypic variation in the
population attributable to the focal gene region reaching a plateau
at ,4% as l increases to ,0.075–0.10 (Figure 1d). Although our
simulations assume a uniform rate of crossing over per generation,
heritability similarly plateaus at ,4% for a region with zero
recombination (Figure S1c) when using the same mutational
parameters as in Figure 1d. Since the power to detect an
association depends on the recombination rate between genotyped
markers and causative mutations, we present results only for the
case of no recombination (representing extreme ‘‘cold’’ regions of
recombination) and for a region recombining at a uniform rate
representing the genome average. Thus, while we are not explicitly
modeling hotspots of recombination, we view the results as
broadly-applicable on average.
The value of heritability at the plateau depends on the model
parameters. Plateau height is approximately linear as a function of
the deleterious mutation rate (Figure S2a), holding all other
parameters the same as Figure 1c. Thus, holding the per-site
neutral mutation rate constant, the heritability due to a gene
region is a function of the proportion of sites mutable to disease
alleles and the physical size of a gene. Further, we can ‘‘tune’’ the
expected value of the heritability at the plateau by increasing or
decreasing the value ofs2s=s
2
E (the ratio of the variance in fitness
and variance due to random effects) in a manner broadly
consistent with the house-of-cards model for the maintenance of
quantitative genetic variation under mutation selection balance
([37]; Figure S2b and S2c). Thus, in spite of the considerable
uncertainty in the values of md (the deleterious mutation rate, or
the product of proportion of sites mutable to a causative allele and
the size of a gene for a constant per site mutation rate) an l (the
average effect size of newly arising exponentially distributed
deleterious mutations), our model is able to generate a single gene
of small to large effect contributing to disease risk for plausible
parameters (Figure S2a). It is additionally noteworthy that the
stochastic variation around the expected gene-specific heritability
(conditional on md and l) is quite large. This implies that even for
parameter combinations that predict equilibrium heritability
values of ,2% (e.g. Figure S2a), 2–9% of genes sharing these
parameters will each account for .5% of the total phenotypic
variation in a complex trait (data not shown). Therefore, despite
our focus on parameter values that result in a heritability plateau
of ,4%, parameter values predicting lower plateaus are clearly of
interest.
Population genetic signatures
We examined the frequencies of mutations in a sample of 100
diploids drawn from each of the simulated regions. On average,
causative mutations are more rare than expected in the absence of
natural selection (Figure S3a–S3d). The strength of the skew
towards rare alleles is stronger with increasing l, consistent with
the observation that at the heritability plateau, larger l are
associated with variation being due to fewer (Figure S3e), more
rare (Figure S3f), and larger-effect mutations compared to small l.
In contrast, the site frequency spectrum at non-causative variants
is indistinguishable from neutrality irrespective of l. As the vast
majority of polymorphisms are non-causative under our model
(Figure S3f), it is unlikely that population-genetic methods would
identify these gene regions as abnormal, despite their strong
contribution to disease. Thus, under our model there is only a very
slight excess of rare alleles observed in case versus controls (Figure
S3e), and this is not likely a fruitful signal to look for. It is
GWAS and Disease Risk Due to Mutations in Genes
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Figure 1. Phenotypes under the gene-based model. (a) Phenotype depends only on the number of causative mutations present on each
haplotype, and not on whether an individual is homo- or heterozygous for particular mutations. Thus, the two diploids shown are equivalent in their
expected phenotype, as both diploids contain one haplotype with two causative mutations, and a second haplotype with three such mutations. (b)
Phenotype is calculated as the geometric mean of the effects of each haplotype, and is therefore determined primarily by the haplotype closest to
wild-type. The panel shows the expected phenotype for diploids with different combinations of mutations on each haplotype, assuming a constant
effect size of 0.05 per mutation. (c) Quantile-quantile plots of phenotypes resulting from the simulation. The x-axis is the quantiles of a unit Gaussian,
and the y-axis is the z-score normalized quantiles observed in a simulated population. For three different parameter values, the phenotypes of 20,000
diploids from a single simulated population are shown. At moderate average effect sizes (l) (0.10 in the panel), there tends to be an excess of
individuals with modestly-large phenotypes, whereas with large l, a population typically contains proportionally more individuals with large
phenotypic values. (d). Broad-sense heritability as a function of l, the mean effect size of a causative disease mutation. Plotted are the mean values
61 standard deviation, calculated from the simulation output.
doi:10.1371/journal.pgen.1003258.g001
GWAS and Disease Risk Due to Mutations in Genes
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important to note that this result may not extend to ‘‘exon
sequencing’’ where there may indeed be an excess of rare non-
synonymous (NS) SNPs in cases relative to controls. If disease is
primarily due to rare NS mutations in genes making strong
contributions to total risk, the fraction of NS SNPs mutable to
causative alleles is likely much greater than the same fraction for a
gene region in general (including non-coding regulatory regions) as
modeled here.
Some properties of GWAS signals
Figure 2 shows representative Manhattan plots (based on a
marker-by-marker logistic regression of 3000 case/control sam-
ples) for 100 kb gene regions and different l (l=0 is a no
deleterious mutation control simulation). Since we track every
SNP in a region, we can distinguish neutral from causative
markers as well as common from rare markers. For both large and
small l, it is difficult for markers from either SNP-chips or
complete resequencing studies to reach a genome-wide statistical
significance threshold (Figure 2a, 2b, and 2f; we assume SNP-chips
type exclusively SNPs with a MAF $5% and all such SNPs are
genotyped). For intermediate l it is possible for markers to be
significant at a genome-wide threshold, and rare markers are more
likely to approach significance than intermediate-frequency
markers (Figure 2c–2e). For intermediate l, only a small
percentage of rare sites are causative (,10% on average for all
l), yet causative sites are much more likely to be among those
markers reaching significance than non-causative sites (17.6% to
31.3% of significant rare markers are causative; Figure S4a). Thus,
unlike current GWAS using intermediate frequency markers,
under our gene-based model significant associations between rare
markers and disease status are likely to identify truly causative
mutations.
We also observe examples of significant, common, non-
causative markers (e.g. Figure 2c), consistent with current GWAS
hits occasionally uncovering genes evolving under our gene-based
model. In general, significant common markers are only in strong
linkage disequilibrium with a single causative SNP (Figure S4b);
similarly, when several common non-causative markers are
significant in a single region, they tend to ‘‘tag’’ different causative
SNPs (Figure S4c), which themselves tend to be surprisingly
common with small effect sizes (Figure S4d). Thus, an individual
significant common neutral marker is typically associated with a
single causative site of weak effect that has drifted to an
intermediate frequency (i.e., an evolutionary outlier). This
observed relationship between common SNPs significant in a
GWAS and causative alleles is inconsistent with the claim of
recently published work that introduced the idea of a synthetic
association resulting from a common marker tagging a haplo-
type(s) harboring an excess of rare causative mutations [19,38]. It
is likely this difference stems from the fact that the synthetic
association papers assume causative alleles are neutrally evolving,
yet narrowly constrained in allele frequencies, whereas here we
assume causative alleles are deleterious with equilibrium frequen-
cies and patterns LD ultimately determined by evolutionary forces.
The power of marker-by-marker GWAS to identify genes
We estimated the power of the widely-used logistic regression
approach to identify regions containing at least one significant
marker. For the parameters simulated, power maximizes at 28%
in a GWAS using common markers and at 38% in a resequencing
study, when l=0.075 (Figure 3a). When l=0 (no deleterious risk
mutations present), power is 0 at significance level a=1028.
Further, the cumulative distribution of p-values for l=0 is a line
with a slope less than one, indicating that the logistic regression test
is conservative when applied to our simulated data (data not
shown). For small values of l.0, broad-sense heritability is also
lower (Figure 1d), resulting in less power. As l increases broad-
sense heritability reaches a plateau (Figure 1d), but after that
plateau is reached power begins to decrease as causative variants
become more and more rare in the general population (Figure 3a,
Figure S4). Thus, depending on the value of the largely unknown
parameter l, current approaches based on common markers have
limited power to identify genes harboring causative deleterious
alleles, consistent with the idea that some of the ‘‘missing
heritability’’ associated with current generation GWAS is due to
RALE. Although we are not the first to point this out (c.f. [2]),
complete resequencing of cases and controls may only yield a
modest improvement in power under a marker-by-marker GWAS
(Figure 3a). Finally, the power of GWAS and resequencing studies
to identify gene regions is only slightly higher in a region of zero
recombination (Figure 3a).
The power of existing tests for RALE
We applied Madsen and Browning’s rank-sum test [16], Li and
Leal’s multiple marker test [15], and the software package SKAT
[21,29,30] to our simulated data. The first two tests have been
proposed to detect an excess of rare alleles amongst cases for gene
regions (typically genes, or a fixed physical sliding window). We
employed a p-value threshold of 1026 (compared to the more
conservative 1028 for a SNP-by-SNP GWAS) for these gene-based
tests, as they integrate over markers, and thus fewer tests are
carried out when doing a genome-wide scan. The Madsen and
Browning test results in an excess of small p-values (compared to
the same test in l=0 controls) across a wide range of l, with the
excess being greater in resequencing studies than chip-based
GWAS (Figure S5a–S5j), but the p-values are rarely small enough
to reach genome-wide significance. As a result power maximizes at
5.2% for resequencing studies and intermediate l (Figure 3b). In
contrast, the Li and Leal multiple marker test shows no
enrichment for small p-values (Figure S6a–S6j), and power ,1%
for all l (Figure 3c). In the absence of recombination, the Madsen
and Browning test shows a greater excess of small p-values and
power maximizes at 13.6% when l=0.025 (Figure 3b, Figure S7).
The power of the Li and Leal test was unchanged in the absence of
recombination (Figure S8 and Figure 3c). Both the Madsen and
Browning and Li and Leal tests are designed to detect an excess of
rare alleles in cases versus controls. However, under our model
there is only a very slight excess of rare variants in cases relative to
controls at disease genes. This is because the proportion of rare
variants that are disease-causing (as opposed to neutral) in a gene
region at equilibrium is small and the sampling variance on this
proportion is large under the mutation-selection balance model we
consider. Although the test statistics proposed by Madsen and
Browning and by Li and Leal are reasonable, the information they
are exploiting, which depends on a net excess of rare alleles in
cases, is generally unable to distinguish cases from controls when
applied to our simulated data. We note that it is possible that the
Madsen and Browing and the Li and Leal tests would be more
powerful when applied to a subset or markers chosen a-priori to be
potentially functional. However, the high variance in the
relationship between effect size and average allele frequency of a
causative deleterious marker (see Figure 2 of [23] for the case of
multiplicative fitness effects) suggests that the signal-to-noise ratio
may still remain low.
The power of the SKAT software to detect associations in
recombining regions is shown in Figure 3d. For GWA studies,
power peaks at 27.2% when l=0.05. The two weighting schemes
applied to individual markers (see Methods) result in similar power
GWAS and Disease Risk Due to Mutations in Genes
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profiles. For resequencing studies, power maximizes at 54.5%
when l=0.05, with the power being greatest when using Madsen
and Browning’s [16] weighting scheme for individual markers
(Figure 3d; Madsen Browning weights are not equivalent to the
test proposed in [16]). When applied to non-recombining regions,
we observe approximately 10% less power across all effect sizes,
Figure 2. Representative Manhattan plots. The dashed horizontal line corresponds to a p-value of 1028. (a–f) The 2log10 of the p-value of the
logistic regression is shown for representative examples for different mean effect sizes of causative mutations (l). The plots are separated into four
classes of mutations: common neutral and causative variants, which could be typed in a GWAS, and rare neutral and causative variants which would
only be directly typed by resequencing.
doi:10.1371/journal.pgen.1003258.g002
GWAS and Disease Risk Due to Mutations in Genes
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and the different weighting schemes give similar power profiles for
both GWAS and resequencing studies (Figure 3e).
Our model suggests new alternative statistical tests
An interesting feature of the Manhattan plots (Figure 2) is that
for all but the highest values of l we observe a ‘‘genetic signature’’
of a gene contributing to a complex phenotype that consists of a
large number of markers with suggestive, but not globally
significant, p-values (e.g., contrast Figure 2a with b–e). Upon
further examination the majority of the tagged causative mutations
are rare in the population and, since they tend to occur on
different genetic backgrounds, are only weakly correlated with
one-another. This observation suggests that the design and
implementation of a statistical test that integrates over approxi-
mately independent rare markers located in a gene-region is a
fruitful avenue for future research. We applied a new statistical test
(ESM, described in Methods) to our simulated gene regions to
determine if there is information not currently being exploited by
published statistical tests. The ESM test statistic is the sum of the
difference in the observed and expected p-values (on a log10 scale)
of the M most significant markers in a genomic region (see
Methods for details). Control simulations with no causative
mutations show that a permutation procedure (see Methods)
results in the correct distribution of p-values (Figure S10a) and a
power of zero at a significance threshold of 1026 (Figure 3f). The
ESM statistic is the most powerful of all the statistics evaluated
under either a common marker GWAS or resequencing exper-
imental paradigm, with complete resequencing giving the highest
power than GWAS over all values of l. When only common
markers are genotyped the marker-based logistic regression and
SKAT are the second and third most-powerful approaches
respectively (Figure 3a and 3d), whereas SKAT is the second
most-powerful approach under resequencing (compare Figure 3d
to Figure 3f). For l in the range of 0.05–0.15, the power of the
ESM test can approach 77% and the power only drops below 20%
for l.0.35. In the absence of recombination, power can be as
high as 82% for intermediate l (Figure 3f). The statistical
properties of this statistic are detailed in Figures S9 and S10.
Such a test could be implemented genome-wide using a sliding-
window or a gene-centric approach. We developed this test to
serve as an illustrative example of a test that attempts to integrate
information over a gene-region, and we suspect that more
sophisticated tests could be designed to detect the cumulative
effects of rare variants in a gene region.
The ‘‘missing heritability problem’’ of current GWAS
Goldstein and colleagues [19,38] have proposed that common
variants may be tagging haplotype(s) harboring several low
frequency causative alleles. However, their model assumes that
causative mutations may be modeled by placing them on neutral
genealogies within a small window of frequencies [19]. When both
the effect sizes and allele frequencies of causative polymorphisms
are random outcomes of the evolutionary process, we observe that
significant common variants tend to tag a single causative variant
(Figure S4c) of small effect that has drifted to modest frequency
(Figure S4d). If RALE are deleterious instead of neutral, this
observation casts doubt on the claim that common variants
generally tag haplotypes harboring several low-frequency causative
alleles. Our results suggest a different interpretation of missing
heritability, one which is consistent with standard population-
genetic predictions of an inverse relationship between frequency
and the effect size of a deleterious mutation [11,12,23].
Conditional on observing a significant common marker near a
gene experiencing recurrent deleterious mutations, that marker
likely tags a single causative SNP whose effect size is small enough
(and therefore selection weak enough) that that mutation drifted to
high frequency. Thus, the missing heritability in our simulations is
due to that single association tagging only one out of several
causative variants segregating in a region, with the effect size of
that tagged mutant being smaller than that of others segregating in
the region. We note that this phenomenon is not unique to the
model simulated here. Any evolutionary model with a distribution
of negative selection coefficients associated with newly arising
deleterious mutations will predict an inverse relationship between
population frequency and selection coefficient, conditional on a
variant segregating in the population (e.g. [23]). Consistent with
this hypothesis, the mean number of singletons on a haplotype
defined either by the number of copies of the derived allele at the
most significant marker in a GWAS, or by the number of copies of
the derived allele at a SNP not associated with case control status,
do not differ appreciably for the parameters considered here
(Figure S11). Therefore, under the gene-based mutation-selection
balance model considered here, significant associations are not
tagging haplotypes with unusual numbers of rare alleles on
average (c.f. 19).
Wray et al. [28] have pointed out that the allele frequencies of
strongest associations in current GWAS are nearly uniformly
distributed (see their Figure 2a). We sampled markers from our
simulated case/control samples such that the MAF on GWAS
chips are uniformly distributed (Figure 4a). This distribution
matches the simulated MAF distribution in [28] and that seen on
SNP chips. When we use such a SNP chip to carry out GWAS
under our evolutionary model of RALE, the resulting MAF
distribution at significantly associated SNPs appears rather
uniform, with a slight excess toward intermediate MAF for some
l (Figure 4b–4f). Thus our simulations are consistent with the
results of current GWAS, and inconsistent with Dickson and
colleagues [19,38] as represented in [28] (c.f., their Figure 2). We
conclude that many currently reported associations presumably
reflect bona fide intermediate frequency variants, and that the
‘‘missing heritability’’ problem may arise from GWAS being
biased towards detecting associations with causative mutations of
small effect relative to the average effect size at a causative gene.
Discussion
Risch [39,40] presented an early and influential attempt to
model the genetics of complex traits and to frame the model in
terms of measurable parameters such as relative risk. For a given
locus, he considered the case of a single risk allele (the product of a
single mutational event some time in the past) with some specified
effect size. Risk alleles at different genes interact multiplicatively to
generate an individual’s phenotype, a common assumption in
multi-locus models in evolutionary biology [41,42]. Risch and
Merikangas [13] used this model to calculate the power to detect a
Figure 3. Power to identify regions containing causative mutations. (a) The power of the logistic regression in GWAS and resequencing
studies at significance threshold a=1028. (b) The power of Madsen and Browning’s [16] test (at a= 1026). (c) The power of Li and Leal’s [15] multiple-
marker test (at a= 1026). (d) Power (at a=1026) using the SKAT software package, applied to data from recombining regions. (e) Power (at a= 1026)
using the SKAT software package, applied to data from non-recombining regions. (f) The power of the ESM test (at a=1026, see Methods) in GWAS
and resequencing studies.
doi:10.1371/journal.pgen.1003258.g003
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Figure 4. Frequencies of most significant markers (based on the logistic regression test) in GWAS based on genotyping panels of
previously ascertained SNPs. (a) From our simulated case-control studies, we randomly-sampled markers in order to mimic the ascertainment of
common markers typical of current GWAS, which resulted in a uniform distribution of minor allele frequencies. The distribution shown here is
summed across all replicate simulations of a gene region. (b–f) Monte Carlo estimates of the expected number of most-associated markers in
different frequency intervals for different values of l (the mean effect size of a causative mutation). The x-axis represent the frequency of the minor
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risk allele at an arbitrary frequency in the population. Pritchard
[11] was the first to add explicit evolutionary considerations to this
model, extending Risch’s model to the case of a constant-size,
randomly-mating population subject to recurrent mutation to risk
alleles at multiple loci (with constant effect sizes of risk alleles at a
single locus, but varying across loci), multiplicative interaction
between loci, and natural selection against risk alleles. In
Pritchard’s model, the equilibrium frequency distribution of the
risk allele class at a single locus is known from population genetics
theory ([43], also see equation 1 of [11]), and the frequency of the
risk allele class is the sum of the frequencies of the individual
susceptibility alleles that have arisen independently at different
positions in a non-recombining region. Pritchard’s model was an
important conceptual advance, allowing the frequencies of the risk
allele class to be the random output of the interplay between
recurrent mutation, genetic drift, and natural selection. However,
due to computational constraints, Pritchard did not explicitly track
the frequency of each individual mutation within the risk allele
class, nor did he incorporate neutral markers into the model.
These two limitations, and the assumed lack of recombination
within loci, prevented him from explicitly evaluating the power to
detect associations in the case where risk alleles at a single gene are
the result of different mutational events embedded in a genomic
region consisting largely of linked neutral SNP markers.
Since Pritchard’s [11] paper, the application of population-
genetic principles to our understanding of the properties of GWAS
has been heterogeneous. Rather than employing explicit simula-
tions of the evolution of a disease phenotype, recent studies have
employed a variety of approximations ([11,15–17,19–21,24–
25,29], also see Introduction), largely due to computational
constraints, and possibly due to the lack of appropriate simulation
machinery (but see [44]). As a result, much of the theoretical/
statistical current literature on RALE does not incorporate a
notion of a gene (e.g. [26]) and statistical methods are rarely tested
on simulated data that can be described as outcomes of a
biological or evolutionary process. Therefore, to more accurately
model the ability of GWAS to identify a gene-region harboring
RALE, new evolutionary models of gene action are required that
are based on a standard well-accepted definition of a gene [26].
Several studies that have carried out resequencing of candidate
gene exons in case/control samples have observed an excess of
rare non-synonymous mutations in the cases [3–8]. Implemented
on a genome-wide scale, this ‘‘exomics’’ approach to the genetic
dissection of complex traits would most certainly pay dividends
[45]. However, it is important to note that scanning for an excess
of rare variants within cases may be less fruitful when variants
cannot be classified a priori as putatively causative (e.g. focusing on
amino acid variants in coding regions). Our model indeed suggests
that tests focusing on detecting such an excess of rare mutations in
cases have low power when there are no a priori weights applied to
different sites within a region and when causative mutations are a
small fraction of the total number of variants in a region
(Figure 3b–3c, Figure S3e–S3f). These assumptions are likely to
be satisfied if some fraction of complex disease is due to mutations
in cis-regulatory regions and, thus, intuition gained from scanning
for RALE in exons may be misleading.
Our model is consistent with the hypothesis that many rare
variants could exist at a relatively small number of genes, and as a
class those variants are likely to make a measurable contribution to
the variation in complex traits. It is not unreasonable to assume
that those variants are partially recessive and partially fail to
complement one another when located in the same gene. An
important aspect of our model is that causative mutations may be
located anywhere in a large gene region that includes regulatory
and splicing control regions, and causative mutations are not
limited to point mutations. We show that simple extensions to
current marker-by-marker tests have considerable power to detect
genes harboring such variants. GWAS employing common
markers have harvested the ‘‘low-hanging fruit’’ associated with
intermediate frequency causative variants. In light of mounting
evidence that common variants only explain a small fraction of the
genetic variation in complex disease phenotypes, it behooves us to
design experiments that have reasonable power to uncover the
genetic architecture of complex traits under specific population-
genetic models purporting to explain the existence of variation in
these traits. Forward simulations that can track entire gene regions
under intuitively appealing models of gene action and fitness allow
us to assess the power of different experimental designs.
Materials and Methods
Forward simulation
We implemented a forward-time simulation of a Wright-Fisher
population with mutation following the infinitely-many sites model
[46], recombination, and selection occurring each generation. We
simulated a population of N= 20,000 diploids with a neutral
mutation rate of m=0.00125 per gamete per generation, and a
recombination rate of r = 0.00125 per diploid per generation.
These values correspond to the scaled parameters h=4Nm=100
and r=4Nr= 100, and thus correspond to a ‘‘typical’’ 100
kilobase region of the human genome. The mutation rate to
causative mutations was md = 0.1 m per gamete per generation. In
our model, causative mutations are treated as SNPs for simplicity,
but should be viewed more generally as genetic events (including
copy-number variants and transposable element insertions) that we
assume to be detectable via a chip or resequencing assay.
We note that there are a variety of forward-time simulation
programs in the literature. However, the majority of these either
simulate non-gene-based models [22,47,48], models involving only
unlinked makers [49], or only neutral models [50]. Further, none
of them simulate the explicit genotype-phenotype relationship
assumed here (see Introduction).
Model of disease and fitness
An individual carries c1 and c2 causative mutations on each
haplotype. The effect size of the ith mutation on the jth haplotype is
ei,jw0, and the phenotype of an individual is
P=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPc1
i~1 ei,1|
Pc2
i~1 ei,2
p
zx where x is a Gaussian deviate
with mean 0 and standard deviation se, which we fix at 0.075 in
the simulations. In words, the phenotypic effect of a single
haplotype is additive over causal mutations, and the phenotype of
an individual is the geometric mean of the effects of each
haplotype plus Gaussian noise. Since phenotypes are continuous
they represent the underlying liability of developing a disease [51,
chapter 18]. When we refer to heritability and phenotypic
distributions in the population in the text, such references are in
regards to these liabilities. The phenotypes are under Gaussian
stabilizing selection with a standard deviation of ss = 1, and w, the
fitness of a diploid, is proportional to e
{P
2
2s2s .
allele (defined in the general population) in the cases. In each panel, n~x is an estimate of the expected number of replicates (out of a total of 250)
containing at least one significant marker using an imperfect SNP chip.
doi:10.1371/journal.pgen.1003258.g004
GWAS and Disease Risk Due to Mutations in Genes
PLOS Genetics | www.plosgenetics.org 10 February 2013 | Volume 9 | Issue 2 | e1003258
In our simulations, the effect sizes of causative mutations are
exponentially distributed with means of l=0, 0.01, 0.025, 0.05,
0.075, 0.1, 0.125, 0.175, 0.25, 0.35, or 0.5. For each l.0, we
performed 250 independent simulations. For an effect size of 0,
representing ‘‘control’’ simulations where there is no genetic
contribution to risk, we simulated 1000 independent replicates. All
simulations were run for 8N generations prior to sampling.
Exploring the parameter space
For the parameters m=0.00125/gamete, md = 0.1 m, ss = 1,
se = 0.075, and r = 0.00125/diploid or 0, we simulated both
neutral and causative markers, allowing us to examine the
properties of GWAS in detail. In order to reduce computational
time, for all other parameter values explored, we set m=0 (i.e., no
neutral mutations were simulated) and only simulated the
causative sites. By not simulating the neutral mutations, simula-
tions run orders of magnitude faster, allowing us to look at
heritability across a broader parameter space.
Case-control studies
For each simulated population, 3000 cases and 3000 controls
were sampled. A case was defined as being in the upper 15% of the
phenotypic distribution, and controls were within 1 standard
deviation of the population mean. For each case-control panel, we
define a GWAS to include all markers present in the panel with a
minor allele frequency $5%, and a resequencing study to include
all markers. For both types of study, we performed a logistic
regression of case/control status onto genotype under an additive
model.
The significance threshold used was 1028, representing a typical
cutoff used in current GWAS [19,52]. The power simulations refer
to these case/control samples, with power defined as the
proportion of replicate simulations with at least one marker in
the gene region exceeding the genome-wide significance threshold.
Data set availability
The forward simulations required approximately six weeks on a
cluster of 96 computing cores (AMDOpteron 6168, 1900 Mhz). To
facilitate the further development of tests for detecting associations
in gene regions, we have made all source code, forward simulation
output, and case/control files available online at http://www.
molpopgen.org/ThorntonForanLongPLoSGenetics.html.
Gene/region-based tests of association
In addition to the single-marker test, we also applied several
existing and one new test of an association of genotype with case/
control status to our simulated data. For tests applied to a set of
markers within a genomic region, the significance threshold should
be less conservative than the 1028 used for the single-marker test.
Our simulated data are 100 kilobase regions, from a genome of
approximately 36109 base pairs, giving 36109/105 = 36104 non-
overlapping windows. A conservative significance threshold would
thus be 0.05/(36104) = 1.6761026. Here, we take p,=1026 as
the significance threshold for all region-based tests (following, for
example, [21]).
Excess of Significant Markers (ESM) test statistic
We developed a statistical test that attempts to integrate
significance over marginally significant variants in a single gene.
Under the gene-based model, genes harboring causative mutations
tend to display such a genetic signature, and the ESM statistic is
larger when there are more marginally significant mutations in a
genomic region. Given a vector of Fisher’s exact test p-values (p)
comparing allele counts in cases and controls for M unique
markers (i.e., redundant markers collapsed) from a gene region, we
define Y1 to be the largest value of negative base ten logarithm of
p, Y2 the second largest, etc. Then our test statistic is:
ESMM~
XM
i~1
Yizlog10
i
M
  
The rationale for the statistic comes from the fact that, if the data
were truly drawn from the null model of no contribution of
genotype to case/control status, then the expected distribution of
p-values is uniform on the interval (0,1]. In other words, for a large
number of independent tests applied to data from the null model,
the expected fraction of tests with p,=x is x. However, when
data truly come from an alternative model, and a test has power
greater than the false positive rate, the expected fraction of
independent tests with p,=x is greater than x. The ESM statistic
is the sum of the difference between the observed and expected p-
values (on a log10 scale) of the M most significant markers in a
region.
The test statistic was calculated for two different conditions.
First, for GWA studies where, as above, only minor allele
frequencies (MAF) $0.05 were included. The second condition
assumed complete resequencing of individuals and included all
markers. For the latter case, and for GWAS assuming a
recombining region, we considered values of M=50, since the
value of ZM was generally observed to plateau by this point
(averaging the statistic over replicates as a function of M). For
GWAS in non-recombining regions, we considered values of
M=25, as too few simulations had more than 25 unique markers
with the requisite MAF to consider larger M. For both GWA and
resequencing studies, the minimum count of a minor allele had to
be 4 in order for a marker to be included in the analysis.
We have also applied several other ‘‘region-based’’ tests
designed to detect a contribution of rare alleles to disease risk
within a defined genomic region. The first test is Madsen and
Browning’s [16] rank-sum test. This test ranks individuals using a
score that is a function of how many mutations they carry
(weighting the contribution of each mutation to the score by its
frequency in the control individuals), and the statistic is the sum of
ranks in affected individuals. We calculated the test statistic under
Madsen and Browning’s ‘‘general genetic’’ model, where the score
for an individual at a particular marker equals the number of
copies of the minor allele carried by the individual (0, 1 or 2). We
chose this model because, under the genetic model that we have
simulated, it will be rare for affected individuals to be homozygous
for a single causative mutation, implying that the per-marker
recessive model of Madsen and Browning would not be
appropriate. We applied the test to two treatments of the data—
GWAS (MAF.5%), and complete resequencing (no MAF filter).
The second test is Li and Leal’s [15] multiple marker test, which
amounts to calculating Hotelling’s T statistic on a matrix of
genotype scores (aa =21, Aa= 0, AA=1, where a is the minor
allele). We applied this test to either the 50, 100, 200, or 250 rarest
variants (by minor allele frequency) present in a case-control panel.
The Hotelling T statistic was calculated using the ‘‘pseudoinverse’’
function from the ‘‘corpcor’’ library [53] in R [54] for matrix
inversion. In practice, the routines used for the matrix inversions
required to calculate the test statistic were numerically unstable for
larger numbers of markers, resulting in the absence of a p-value for
some replicates.
For Madsen and Browning’s, and for Li and Leal’s, test
statistics, we did not first collapse redundant markers. The
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rationale for not collapsing is that if a ‘‘case’’ contains, for
example, two singleton mutations (e.g., present only once in the
entire case/control panel), then those two mutations would count
more towards case/control differences in the permutation test than
they would in the ESM test statistic. Thus, any differences in the
power between ESM and the other two statistics should be viewed
as conservative.
Finally, we applied the SKAT software [21,29,30] (available
from http://www.hsph.harvard.edu/xlin/software.html) to all of
our simulated data. We applied the software in two different ways.
First, we used default weights on individual markers and the
optimal p-value approach described in [30]. Second, we applied
the marker weights proposed in Madsen and Browning [16] in
combination with the optimal p-value approach. Note that the
latter is not equivalent to Madsen and Browning’s rank-sum test
[16], but is simply a variant of the SKAT procedure using a
different weighting scheme. Because the data are simulated with
no complications such as population substructure, sex-specific
effects of risk alleles, etc., the only covariate needed for the
assessment of significance is the case/control status of individuals.
Evaluation of statistical significance
For the ESM, Madsen-Browning, and Li and Leal tests, we
assessed statistical significance following the permutation proce-
dure outlined in [16]. Case and control labels were permuted 1000
times, resulting in a permutation distribution of the statistic, x.
The observed value of the statistic was converted into a z-score
(z = xobs{xð Þ=sx), where sx is the standard deviation of the
permuted distribution. The distribution of z-scores under the null
model of no association with disease is expected to be a unit
Gaussian with mean 0 (which we confirmed using control
simulations, see panel A of Figures S5, S6, S7, S8, S9, S10),
which was used to calculate two-tailed p-values. The SKAT
software obtains p-values by fitting a logit model to the data [21]
and thus there is no need for permutation.
Simulating properties of GWAS on imperfect chips
In the analyses described above, we assume that a GWA study is
conducted using perfect genotyping technology able to assay 100%
of markers with minor allele frequencies .5%. However, the
majority of GWAS to date have used genotyping chips that assay a
subset of ascertained markers whose minor allele frequencies are
uniform in the range of 0.05 to 0.5 [28]. In order to mimic these
chips, we resample markers from our case/control panels
(described above), including a marker on the ‘‘chip’’ if a uniform
random number on the interval (0,1] is ,= the heterozygosity of
the minor allele in the control population. This sampling results in
sample of markers with a uniform distribution of MAF in the
desired frequency interval, although some MAF may be .0.5
because the minor allele is defined in the general population, and
the control population is a random sample of the general
population.
We use these imperfect chips to look at the MAF distribution of
the most significant marker (defined by a logistic regression test
described above) in a gene region (following [28]). Specifically, we
ask what the frequency of the most significant minor allele is in the
case population. However, as the number of significant markers
per simulated replicate may be quite low (even when using a chip
assaying all markers), the resulting distribution of MAF may be
very noisy. To reduce this noise, we estimate the expected number
of most-associated markers in different frequency bins by
randomly sampling 1,000 imperfect chips from each of our 250
replicate case/control populations for each value of l.
Supporting Information
Figure S1 Phenotypes under an explicit gene-based model. (a)
The model of gene action results in partial recessivity of
haplotypes. The panel shows the empirical cumulative distribution
of phenotypes that result from our simulations with mean effect
size l=0.10 per causative mutation (black line), based on 250
independent simulations. Using the output of each simulation, we
calculated each individual’s phenotype under the standard models
used in quantitative genetics–the additive model (red line),
recessive model (blue line) and dominant model (purple line) of
gene action. These other models were not explicitly simulated.
Rather, the haplotype effect sizes output from our gene-based
simulation were used to generate phenotypes under these
alternative genotype-to-phenotype models. The gene-based model
results in a distribution of phenotypes in between that of the
additive and recessive models. (b) Average fitness of individuals in
the simulations. Red dots show the mean of the population mean
fitness. Blue triangles are the average fitness of individuals in the
upper 15% of the phenotypic distribution of the population, who
were treated as cases in the case-control analyses. The black
diamonds are the mean fitness of the least fit individual observed
in each simulated population. (c) Mean 61 standard deviation of
broad-sense heritability, as a function of l. The points with solid
lines are the same parameters as in Figure 1d (a region where
4Nm=4Nr, where N is the population size, and m and r the
mutation and recombination rates, respectively, and recombina-
tion occurs uniformly along the region). Points with dashed lines
are from simulations with the same model parameters, but with
zero recombination.
(PDF)
Figure S2 Broad-sense heritability in different parts of the
parameter space. (a) The deleterious mutation rate has an
approximately linear effect on broad-sense heritability at large
mean effect sizes of causative mutations (l). All model parameters
except the deleterious mutation rate (md) are the same as in
Figure 1d (see Methods). (b) The mean broad-sense heritability
was estimated from 250 independent simulated populations for
several different parameter combinations, and is shown as a
function of l, the mean effect size of a causative mutation. The
open circles are the same data as Figure 1d, and heritability
plateaus at approximately 0.04 for large l. If the magnitude of
random effects (se) is changed (open triangles and solid diamonds),
heritability plateaus at different values. However, if s2s=s
2
e , where
sS is the variance in fitness, is held constant, heritability plateaus
at approximately 0.04 (solid circles and open, upside-down
triangles), suggesting that s2s=s
2
e is a critical parameter of the
model, as predicted by the house-of-cards model [37]. The
magnitude of the heritability at its plateau appears to be linear as a
function of md, plateauing at approximately 0.02 when the
deleterious mutation rate is halved. (c) Estimated broad-sense
heritability as a function of predicted broad-sense heritability
(h2~ 4mds
2
s
 
= 4mds
2
szs
2
e
 
) under the house-of-cards model (on
a log scale). For 250 replicates with l=0.1,0.125, 0.1275, 0.25,
and 0.5, the mean heritability was calculated. The median of these
five means was used as an estimate of the value of heritability at its
plateau (see panel A). Solid circles represent several different
parameter combinations where s2s=s
2
e.100, where purifying
selection is weak and the house-of-cards assumptions are violated.
The solid black line has slope 1 and intercept log(1) = 0. The
dashed line is the best-fit line with a slope of 1 and an estimated
intercept of 20.6004. This model fits the data better than a model
with slope of 1 and intercept of log(1) (p = 2.61610213,df = 13).
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Thus, the heritability under the gene-based model is roughly one-
half of that predicted under house-of-cards, likely a result of our
assumed weak selection [37]. The two open circles are results from
simulations where s2s=s
2
e,100, which is in the parameter space
covered by house-of-cards, and the observed values are closer, but
still less than, the expected values. This difference is likely due to
the recessive gene action in the simulations, whereas the house-of-
cards model assumes additivity.
(PDF)
Figure S3 Population-genetic properties of a locus. (a–d) The
mean, normalized site frequency spectrum (SFS) of derived
mutations is shown for three different mean effect sizes (l),
calculated from a sample of 100 randomly-chosen diploids from
each simulated population. Shown are the first ten entries of the
SFS for neutral sites (red), causative variants (black), all
polymorphisms (dashed blue), and the expected values for a
Wright-Fisher population experiencing no natural selection (black
circles). (e) Mean (6 J standard deviation) of the number of
causative mutations per diploid in a case/control panel. For both
cases and controls, the mean total number of causative mutations
(open circles) and rare causative mutations (diamonds, derived
allele frequency ,0.05) are shown. (f) Summaries of the amount of
variation in the entire population. Here, S2N refers to the mean
number of mutations present in the entire population, and hp is
the average number of differences between two randomly-chosen
haplotypes [55]. S2N is plotted on a log10 scale. In the absence of
selection, the theoretical expectation of S2N is
h log 2Nð Þz0:6775h [56, p. 298, equation 9.19]. The excellent
agreement between the simulated and the expected value of S2N
for neutral markers for all l shows that the total strength of
selection against causative mutations does not result in a loss of
variability in the region (because selection is weak on a per-marker
basis). For all l, there is at least a 1 order of magnitude difference
in the number of causative and neutral mutations, and hp
decreases for causative markers as l increases, indicating that
causative mutations are more rare on average as a function of
increasing effect size. In the absence of purifying selection, hp
would equal 10 on average at causative sites.
(PDF)
Figure S4 Statistical properties of association studies. (a) Average
proportion of rare variants which are causative in either the general
population, in a case-control panel, or amongst significant markers in
a GWAS where individuals are completely sequenced (b) For every
neutral, commonmarker in a GWAS that was significant in a logistic
regression test at p#1028, we measured LD using the r2 statistic
between the significant marker and all causal markers in the case-
control panel, and recorded the top two r2 values. The distribution of
r2 for the top marker is summarized in white boxplots, and the
distribution for r2 for the second-strongest association is summarized
in red. (c) White boxes summarize the distribution of the number of
significant, common, neutral markers, conditional on there being at
least one such marker. The red boxes summarize the distribution of
the number of unique causal markers amongst the top r2 values for
each significant marker. Taken together, panels a and b suggest that
significant commonmarkers tend to tag a single causative site. (d) For
each of the most strongly-tagged causal mutations making up the red
boxes in panel b, the frequency and effect size of each mutant was
recorded. The frequencies are summarized in the white boxes, and
effect sizes are in red.
(PDF)
Figure S5 Distributions of 2log10 p-values for the Madsen and
Browning [16] statistic. For all panels, the significance threshold of
1026 is shown. (a) The empirical cumulative distribution function
(ECDF) of p-values for control simulations with no deleterious
alleles. As expected, the ECDF of p-values is a straight line with a
slope of approximately 1. (b–k) ECDF of p-values for simulations
with non-zero mean effect sizes of causative mutations (l.0).
(PDF)
Figure S6 Distributions of 2log10 p-values for the Hotelling T
statistic [15]. The statistic was calculated on the rarest 50, 100,
200, or 250 markers. For all panels, the significance threshold of
1026 is shown. (a) The empirical cumulative distribution function
(ECDF) of p-values for control simulations with no deleterious
alleles. The ECDF of p-values is a straight line with a slope of
approximately one when the number of markers is $200. (b–k)
ECDF of p-values for simulations with non-zero mean effect sizes
of causative mutations (l.0).
(PDF)
Figure S7 Distributions of 2log10 p-values for the Madsen and
Browning [16] statistic with no recombination. For all panels, the
significance threshold of 1026 is shown. (a) The empirical
cumulative distribution function (ECDF) of p-values for control
simulations with no deleterious alleles. As expected, the ECDF of
p-values is a straight line with a slope of approximately 1 (b–k)
ECDF of p-values for simulations with non-zero mean effect sizes
of causative mutations (l.0).
(PDF)
Figure S8 Distributions of 2log10 p-values for the Hotelling T
statistic [15] with no recombination. The statistic was calculated
on the rarest 50, 100, 200, or 250 markers. For all panels, the
significance threshold of 1026 is shown. (a) The empirical
cumulative distribution function (ECDF) of p-values for control
simulations with no deleterious alleles. The ECDF of p-values is a
straight line with a slope of approximately 1 when the number of
markers is $200. (b–k) ECDF of p-values for simulations with
non-zero mean effect sizes of causative mutations (l.0).
(PDF)
Figure S9 Distributions of 2log10 p-values for the ESM statistic
(see Methods). For all panels, the significance threshold of 1026 is
shown. (a) The empirical cumulative distribution function (ECDF)
of p-values for control simulations with no deleterious alleles. As
expected, the ECDF of p-values is a straight line with a slope of
approximately 1 (b–k) ECDF of p-values for simulations with non-
zero mean effect sizes of causative mutations (l.0).
(PDF)
Figure S10 Distributions of 2log10 p-values for the ESM
statistic (see Methods) with no recombination. For all panels, the
significance threshold of 1026 is shown. (a) The empirical
cumulative distribution function (ECDF) of p-values for control
simulations with no deleterious alleles. As expected, the ECDF of
p-values is a straight line with a slope of approximately 1. (b–k)
ECDF of p-values for simulations with non-zero mean effect sizes
of causative mutations (l.0).
(PDF)
Figure S11 A comparison of the burden of risk mutations
between significant and non-significant markers in a GWAS.
Shown are mean and standard errors of the number of causative
singletons in individuals with genotypes defined as having either
zero, one, or two copies of the derived allele at the marker most
significantly associated (e.g., the smallest p-value) with case/
control status in a GWAS analyzed by a single-marker test (red).
Pale blue lines show the mean and standard errors of the number
of causative singletons associated with zero, one, or two copies of
the derived mutation of a marker that is both not associated with
GWAS and Disease Risk Due to Mutations in Genes
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case/control status in a logistic regression analysis (p.1024) and
frequency-matched to the most-associated marker in the same
replicate. Each panel of the figure is labeled by the mean effect size
of a causative mutation (l).
(PDF)
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